All In Biotech

Drug Trial Radar · NCT06047379

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

An Open-label Phase 1/2 Dose Finding, Safety and Efficacy Study of Oral NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Uncontrolled Brain Metastasis in Patients With Select Solid Tumors.

Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

134

Planned (sponsor's estimate)

Start

Nov 1, 2023

Primary completion

Feb 28, 2027

Study completion Aug 31, 2027

Sponsor

Lead sponsor
Neonc Technologies, Inc.Industry
Sponsor type
Industry
First posted
Sep 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH- mutant, Glioblastoma IDH-wildtype, and the safety, pharmacokinetics and efficacy of a repeated dose regimen of NEO212 when given with select SOC for the treatment of solid tumor patients with radiographically confirmed uncontrolled metastases to the brain. The study will have three phases, Phase 1, Phase 2a and Phase 2b.

Conditions

  • Diffuse Astrocytoma, IDH-Mutant
  • Glioblastoma, IDH-wildtype
  • Brain Metastases, Adult
  • Cervical Cancer
  • Colorectal Cancer
  • Esophageal Cancer
  • Esophageal Squamous Cell Carcinoma
  • Gastric Cancer
  • Gastroesophageal Junction Adenocarcinoma
  • Head and Neck Squamous Cell Carcinoma
  • Melanoma
  • Merkel Cell Carcinoma
  • Microsatellite Instability-High Solid Malignant Tumor
  • Mismatch Repair Deficient Solid Malignant Tumor
  • Microsatellite Instability-High Colorectal Cancer
  • Mismatch Repair Deficient Colorectal Cancer
  • Non-small Cell Lung Cancer
  • Renal Cell Carcinoma
  • Small Cell Lung Cancer
  • Squamous Cell Carcinoma
  • Urothelial Carcinoma

Interventions

  • NEO212 Oral CapsuleDrug

    NEO212 is a novel chemical entity that was generated by covalent conjugation of temozolomide (TMZ) with perillyl alcohol (POH).

  • IpilimumabDrug

    Ipilimumab, sold under the brand name Yervoy, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system. Cytotoxic T lymphocytes can recognize and destroy cancer cells.

  • PembrolizumabDrug

    Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. It is given by slow injection into a vein.

  • NivolumabDrug

    Nivolumab, sold under the brand name Opdivo, is a medication used to treat a number of types of cancer.

  • RegorafenibDrug

    Regorafenib, sold under the brand name Stivarga among others, is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase. Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition

  • CarboplatinDrug

    Carboplatin, sold under the trade name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer. This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. It is used by injection into a vein.

  • PaclitaxelDrug

    Paclitaxel, sold under the brand name Taxol among others, is a chemotherapy medication used to treat ovarian cancer, esophageal cancer, breast cancer, lung cancer, Kaposi's sarcoma, cervical cancer, and pancreatic cancer. It is administered by intravenous injection

  • FOLFIRI ProtocolDrug

    FOLFIRI is a chemotherapy regimen for treatment of colorectal cancer. It is made up of the following drugs: FOL - folinic acid (leucovorin), a vitamin B derivative with multiple applications, which in this context increases the cytotoxicity of 5-fluorouracil; F - fluorouracil (5-FU), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops synthesis; and IRI - irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating.

  • BevacizumabDrug

    Bevacizumab, sold under the brand name Avastin among others, is a medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: safety and tolerability of increasing dose levels of orally administered NEO212 alone in patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or patients with select solid tumors with uncontrolled metastases to the brainTime frame: 6 months
  2. Phase 1: Identify the maximum tolerated dose (MTD) of NEO212Time frame: 6 months
  3. Phase 1: Determine the recommended Phase 2 dose (RP2D) of NEO212Time frame: 6 months
  4. Phase 2a: Assess the safety and tolerability of orally administered NEO212 in combination with select SOC regimens following a standard 3+3 design in patients with select solid tumors with uncontrolled metastases to the brainTime frame: 6 months
  5. Phase 2b: Determine the intracranial progression-free survival rate at six months (PFS6) of orally administered NEO212 alone in patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype.Time frame: 6 months
  6. Phase 2b: Determine the intracranial progression-free survival rate at six months (PFS6) of orally administered NEO212 in combination with select SOC regimens in patients with select solid tumors with uncontrolled metastases to the brain.Time frame: 6 months

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Precision NextGen Oncology

    Beverly Hills, California · Recruiting

  • OPN Healthcare, Inc

    Glendale, California · Recruiting

  • University of Southern California

    Los Angeles, California · Recruiting

  • MDR Core Network

    Boynton Beach, Florida · Recruiting

  • Tufts Medical Center

    Boston, Massachusetts · Recruiting

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Recruiting

  • Baylor, Scott and White Research Institute

    Dallas, Texas · Recruiting

  • Northwest Medical Specialties

    Tacoma, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.